Space LiinTech, a specialized company in space medicine, announced on the 10th that it has secured Series B funding.
Space LiinTech is a domestic space medicine corporation developing a next-generation biopharmaceutical research and production platform utilizing microgravity environments. Since its establishment in 2021, it has accumulated various technologies in fields such as space protein crystallization. At the end of August, it is set to launch Korea's first space medicine research module.
This investment round saw new participation from reputable institutions, including existing investor Company K Partners, Sunbo Angel Partners, Stick Ventures, Korea Credit Guarantee Fund (KODIT), and D.CAMP. Lee Kang-soo, CEO of Company K Partners, noted, "Space LiinTech is a corporation with limitless growth potential, expanding the use of space into the bio field," adding, "We plan to continuously discover and support innovative companies that will lead the future space industry."
Currently, Space LiinTech is jointly developing automated experimental devices for space-based new drug development in collaboration with the Korea Institute of Science and Technology (KIST) and Harvard Medical School, and is preparing for an experimental launch to the International Space Station (ISS) in August of this year. Domestically, it is also working to establish a space medicine ecosystem by integrating transportation and recovery technologies in collaboration with INNOSPACE, Intergravity Technologies, and others.
Yoon Hak-soon, CEO of Space LiinTech, stated, "Space medicine is a future industry where physics, life sciences, and medical technology converge," and added, "This investment will provide a practical foundation for Korea to lead the space bio market."